

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.weylo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,199	06/09/2005	Guido Bold	ON/4-32798A	1806
75974 7599 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 220 MASSACHUSETTS AVENUE			EXAMINER	
			ANDRES, JANET L	
CAMBRIDGE, MA 02139			ART UNIT	PAPER NUMBER
			1625	
			NOTIFICATION DATE	DELIVERY MODE
			01/28/2011	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

NIBR.MAILDATA@NOVARTIS.COM PATRICIA.HOFSTETTER@NOVARTIS.COM

Application No. Applicant(s) 10/538.199 BOLD ET AL. Notice of Abandonment Examiner Art Unit 1625 Heidi Reese

The MAILING DATE of this communication appears on the cover sheet with the correspondence address	
This application is abandoned in view of:	
 Applicant's failure to timely file a proper reply to the Office letter mailed on 10 June 2010. A reply was received on (with a Certificate of Mailing or Transmission dated), which is after the expiration of period for reply (including a total extension of time of month(s)) which expired on A proposed reply was received on but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final reje (A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal teg); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114). A reply was received on but it does not constitute a proper reply, or a bona filed attempt at a proper reply, to the not 	ction.
final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below). (d) ⊠ No reply has been received.	
(d) M No reply has been received.	
 2. Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three more from the mailing date of the Notice of Aliowance (PTOL-85). (a) The issue fee and publication fee, if applicable, was received on (with a Certificate of Mailing or Transmission), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the Noi 	dated
Allowance (PTOL-85).	
(b) The submitted fee of \$ is insufficient. A balance of \$ is due.	
The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$	
(c) The issue fee and publication fee, if applicable, has not been received.	
 3 Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37). (a) Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which it 	s
after the expiration of the period for reply.	
(b) No corrected drawings have been received.	
 The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or a the applicants. 	ll of
 The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFF 1.34(a)) upon the filing of a continuing application. 	I
 The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court re of the decision has expired and there are no allowed claims. 	eview
7. The reason(s) below:	
/Janet L. Andres/ /Heidi Reese/	
Supervisory Patent Examiner, Art Unit 1625 Examiner, Art Unit 1625	
Detitions to review under 27 CED 1 127(a) or (b) or requests to withdraw the helding of abandanment under 27 CED 1 121 should be promptly filed	440

restions to revive under 37 CFR 1.137(a) or (b), or requests to withd minimize any negative effects on patent term.

US Patent and radorest/ Office PTOL-1432 (Rev. 04-01)